Loading…
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | $-74M | $-65M | $-47M | -63.0% | -58.2% | -50.8% |
| 2024 | $19M | $-52M | $-132M | $-56M | -84.9% | -40.1% | 49.3% |
| 2023 | $31M | $-115M | $-88M | $-80M | -56.3% | 5.0% | 1.8% |
| 2022 | $30M | $-84M | $-87M | $-68M | -44.0% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 29.75 | 31.25 | 18.72 | 7.83 |
| Operating Revenue | - | 29.50 | 31.25 | 18.72 | 7.83 |
| Cost Of Revenue | - | 11.96 | 18.08 | 15.46 | 7.28 |
| Gross Profit | - | 17.79 | 13.17 | 3.26 | 0.54 |
| Operating Expense | - | 102.95 | 129.48 | 55.79 | 74.62 |
| Research And Development | - | 77.81 | 98.38 | 33.59 | 52.64 |
| Selling General And Administration | - | 25.13 | 31.10 | 22.20 | 21.97 |
| Total Expenses | - | 114.91 | 147.56 | 71.25 | 81.90 |
| Operating Income | - | -85.15 | -116.31 | -52.53 | -74.08 |
| Total Operating Income As Reported | - | -89.85 | -97.36 | -141.93 | -76.38 |
| EBITDA | - | -84.36 | -115.45 | -51.72 | -73.62 |
| Normalized EBITDA | - | -79.66 | -134.41 | 37.68 | -71.32 |
| EBIT | - | -85.15 | -116.31 | -52.53 | -74.08 |
| Interest Income | - | - | - | 7.95 | 7.64 |
| Net Interest Income | - | - | - | 7.95 | 7.64 |
| Other Non Operating Income Expenses | - | 2.95 | 8.51 | 1.91 | 3.82 |
| Other Income Expense | - | -1.75 | 27.47 | -87.49 | 1.52 |
| Interest Income Non Operating | - | - | - | 7.95 | 7.64 |
| Net Non Operating Interest Income Expense | - | - | - | 7.95 | 7.64 |
| Pretax Income | - | -86.91 | -88.85 | -132.06 | -64.92 |
| Tax Provision | 0 | 0 | -0.37 | 0 | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0.08 | 0 | 0 |
| Net Income Continuous Operations | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income From Continuing And Discontinued Operation | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income From Continuing Operation Net Minority Interest | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income Common Stockholders | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Net Income Including Noncontrolling Interests | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Normalized Income | - | -82.21 | -107.36 | -42.66 | -62.62 |
| Diluted NI Availto Com Stockholders | - | -86.91 | -88.48 | -132.06 | -64.92 |
| Basic Average Shares | 56.73 | 65.21 | 69.81 | 77.30 | - |
| Diluted Average Shares | 56.73 | 65.21 | 69.81 | 77.30 | - |
| Reconciled Depreciation | - | 0.80 | 0.86 | 0.81 | 0.45 |
| Reconciled Cost Of Revenue | - | 11.96 | 18.08 | 15.46 | 7.28 |
| Total Unusual Items | - | -4.70 | 18.96 | -89.40 | -2.30 |
| Total Unusual Items Excluding Goodwill | - | -4.70 | 18.96 | -89.40 | -2.30 |
| Net Income Discontinuous Operations | 0 | 0 | - | - | - |
| Special Income Charges | - | -4.70 | 18.96 | -89.40 | -2.30 |
| Other Special Charges | - | - | 6.63 | 86.90 | - |
| Write Off | - | 0 | 1.31 | 0 | - |
| Impairment Of Capital Assets | 0 | 0 | 6.63 | - | - |
| Restructuring And Mergern Acquisition | - | 4.70 | -26.90 | 2.50 | 2.30 |
| General And Administrative Expense | - | 25.13 | 31.10 | 22.20 | 21.97 |
| Other Gand A | - | 8.96 | 10.80 | 8.63 | 7.05 |
| Salaries And Wages | - | 16.17 | 20.30 | 13.57 | 14.92 |
| Other Operating Expenses | - | - | - | -1.91 | -3.82 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc.this co. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Zevra Therapeutics, Inc. | ZVRA | $660M |
| - |
| - |
| - |
| - |
| - |
| - |
| 7.93 |
| 4.27 |
| 53.8% |
| 6.70 |
| SI-BONE, Inc. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Peer Median | - | -3.88 | 3.44 | -21.7% | -2.95 | |